A new gold(III) complex bearing a 2-((2,20-bipyridin)-5-yl)-1Hbenzimidazol- 4-carboxamide ligand has been synthesized and characterized for its biological properties in vitro. In addition to showing promising antiproliferative effects against human cancer cells, the compound potently and selectively inhibits the zinc finger protein PARP-1, with respect to the seleno-enzyme thioredoxin reductase. The results hold promise for the design of novel gold-based anticancer agents disrupting PARP-1 function and to be used in combination therapies.
Toward anticancer gold-based compounds targeting PARP-1: A new case study
CITTA, ANNA;SCALCON, VALERIA;FOLDA, ALESSANDRA;RIGOBELLO, MARIA PIA;
2016
Abstract
A new gold(III) complex bearing a 2-((2,20-bipyridin)-5-yl)-1Hbenzimidazol- 4-carboxamide ligand has been synthesized and characterized for its biological properties in vitro. In addition to showing promising antiproliferative effects against human cancer cells, the compound potently and selectively inhibits the zinc finger protein PARP-1, with respect to the seleno-enzyme thioredoxin reductase. The results hold promise for the design of novel gold-based anticancer agents disrupting PARP-1 function and to be used in combination therapies.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
RSCAdv Au-PARP1 2016.pdf
accesso aperto
Tipologia:
Published (publisher's version)
Licenza:
Accesso libero
Dimensione
275.8 kB
Formato
Adobe PDF
|
275.8 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
